Nice

Views & Analysis

Patient on hospital bed with saline solution tube

Will UK patients get access to novel drugs?

Access to new medicines is not high up the list of priorities for NHS England, but pharma must seize opportunities to promote innovation uptake.

News

Kadcyla finally gets OK after price cut and NICE concessions

Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE.

News

Lilly’s sarcoma drug Lartruvo recommended via Cancer Drugs F...

Lilly's drug will be re-appraised in 2020

News

Amgen’s myeloma treatment Kyprolis gains NICE approval

NICE has recommended Amgen’s multiple myeloma treatment Kyprolis, a next generation drug which has shown itself superior to Janssen’s standard treatment Velcade.

News

Scotland decision helps Opdivo in UK market access picture

The last 18 months has seen groundbreaking cancer immunotherapies, led by BMS’s Opdivo and Merck Sharp & Dohme’s Keytruda hit the UK market, with both rapidly adding multiple indication

News